RT Book, Section
A1 Koshkin, Vadim S.
A1 Small, Eric J.
A2 McAninch, Jack W.
A2 Lue, Tom F.
SR Print(0)
ID 1171181029
T1 Systemic Therapy of Urologic Tumors
T2 Smith & Tanagho's General Urology, 19e
YR 2020
FD 2020
PB McGraw Hill
PP New York, NY
SN 9781259834332
LK accesssurgery.mhmedical.com/content.aspx?aid=1171181029
RD 2024/04/23
AB The  use  of  chemotherapy,  targeted  therapeutics,  and  more  recently  immunotherapy  (see  Chapter  25)  in  the  treatment  of  malignant  tumors  of  the  genitourinary  system  serves  as  a  paradigm  for  a  multidisciplinary  approach  to  cancer.  The  careful  integration  of  surgical  and  systemic  treatments  has  resulted  in  impressive  advances  in  the  management  of  urologic  cancers.  By  definition,  surgical  interventions  are  directed  at  local  management  of  urologic  tumors,  whereas  chemotherapy  and  biologic  therapy  are  systemic  in  nature.  Although  there  is  no  question  that  there  are  times  in  the  natural  history  of  a  genitourinary  tumor  when  only  one  therapeutic  method  is  required,  a  multidisciplinary  approach  is  usually  beneficial.  This  chapter  details  the  importance  of  a  joint  surgical–medical  approach  to  patients  with  urologic  malignancies.  A  practicing  urologist  should  collaborate  closely  with  a  medical  oncologist  and  should  feel  comfortable  speaking  with  patients  about  the  uses,  risks,  and  benefits  of  chemotherapy,  and  other  forms  of  systemic  therapy  such  as  tyrosine  kinase  inhibitors  (TKIs)  or  immunotherapy.  The  role  of  immunotherapy  in  the  management  of  genitourinary  tumors  is  covered  in  Chapter  25.